IL18 and atherosclerosis: In diabetic ApoE−/− mice model, cPKCβ can damage vascular endothelial cells through the IL-18/IL-18 binding protein pathway, promote the formation of atherosclerosis, and cPKCβ inhibitor can relieve the progression of atherosclerosis [22].